

2024 Summer Symposium and Reception

Saturday, June 1, 2024, 5:30 pm – 10:00 pm

The Metropolitan in Willis Tower • 233 South Wacker Drive, 66th Floor • Chicago, Illinois 60606



2024 Corporate Partners





2024 Annual Oncology Supporters





Bronze Sponsor



Exhibitors







FIND THE SUPPORT YOUR PATIENTS NEED WITH VERZENIO

Access resources at Verzenio.com







CONTENTS

Event Sponsors	Inside front cover
About CAHON	page 4
Upcoming CAHON Events	page 6
Program	page 7
About Our Speakers	page 8
CAHON Young Investigator Awards	page 9



ABOUT CAHON

Founded by Chinese American Hematologists and Oncologists in 2005, the primary missions of CAHON are to foster communications amongst Chinese American medical professionals for the delivery of high-quality health care to patients with neoplastic and hematological diseases, and to promote medical information exchange between the United States and China in the field of hematology and oncology. CAHON strives to serve as a bridge among its members and between Chinese and American Hematology-Oncology communities for medical and educational exchange.

THE STORY BEHIND THE LOGO

CAHON'S logo was designed by Drs. Weijing Sun, Ke Liu, and Jeffrey Ye, under the supervision of the CAHON Board. The design has the following elements and takes the following considerations:

- The overall shape represents the globe.
- The blue, white, red and yellow represent the colors of two nations' flags. China and the US.
- The yellow and red stripes above the blue, represent bridges. One of CAHON's key missions is to serve as a bridge between Chinese American Hematology-Oncology communities for medical and educational exchange.
- The white space is in the shape of a heart. The hearts of our members continue to drive our mission to provide high quality patient care to everyone.

CAHON MEMBERSHIP

Apply to become a CAHON Member at cahon.org

Value of a CAHON Membership

By joining CAHON you will have access to:

- A growing network of Chinese American professionals working in your field;
- A private WeChat group where you can submit clinical questions to respected colleagues who are knowledgeable in specific areas of hematology and oncology;
- Reduced or waived registration fees for all CAHON events and meetings along with priority hotel reservations;
- Members-only section of the CAHON website featuring the member directory; and
- Travel award opportunities.

MEMBERSHIP CATEGORIES

Regular/Active Membership Associate Membership Allied Membership

Visit cahon.org/membership for more information on membership.





HINISION what's possible

Connect with the Novartis team for more information



Scan here to learn more about PLUVICTO

じNOVARTIS

Save the Dates!

11TH ANNUAL NEW YORK ONCOLOGY FORUM (NYOF)

Saturday, October 5 & Sunday, October 6, 2024 Sheraton La Guardia East Flushing, NY

The CAHON annual New York Oncology Forum (NYOF) is a one-and-a-half-day educational program that includes presentations on new developments and updates from the latest ASH, ASCO and SITC meetings including novel agents for Hematology and Oncology. 2024 will mark the 11th anniversary of this annual event and it draws more than 100 clinicians, researchers, medical students, clinical fellows as well as laboratory and health care related scientists working in hematology and oncology. Approximately 70% of the attendees practice regionally, and 30% travel from other parts of the country.

WINTER SYMPOSIUM AND RECEPTION

Friday, December 6, 2024 University Club Atop Symphony Tower San Diego, CA

Held in conjunction with ASH, the Winter Symposium will offer expert perspectives and practical insights on current advancements in a variety of cancer treatments, as well as foster collaboration and provide a forum for interaction and collaboration between hematologists and oncologists.









Program

5:30 – 7:00 pm	Doors and Registration Open, Social Gathering, Visit Exhibit Booths
7:00 – 7:45 pm	CAHON Presentations Opening Remarks and Board of Directors Updates RuiRong Yuan, MD, PhD – Board Chair
	CAHON Presidential Address and CAHON Updates Bo Zhao, MD – President
	Updates on CAHON Journals Delong Liu, MD, PhD – <i>Editor-in-Chief, Journal of Hematology & Oncology</i>
7:45 – 8:40 pm	Scientific Presentations
7:45 – 8:00 pm	GI Cancer Clinical Research Landscape in China Lin Shen, MD – Beijing Cancer Hospital, China
8:00 – 8:20 pm	Global Collaboration and the AARC Task Force on Asian/Asian-American Issues Lillian L. Siu, MD – President-elect AARC
8:20 – 8:35 pm	Drug Development at SCRI: How to Bring Clinical Trials to More Patients in the Community Melissa Johnson, MD – Sarah Cannon Cancer Institute, USA
8:40 – 8:55pm	Young Investigator Awards Ceremony J Christine Ye, MD Zhaohui Jin, MD Tian Zhang, MD, MHS Wanqing Iris Zhi, MD, PhD CAHON 2022-2024 Academic Committee
8:55 – 9:10 pm	Closing Remarks RuiRong Yuan, MD, PhD & Bo Zhao, MD
	Introduce the next term CAHON Leaders (June 04, 2024-June 04, 2026) Jing-Zhou Hou, MD, PhD, Board Chair & Liang Deng, MD, PhD, President
9:10 – 10:00 pm	Social Gathering

Meeting Organizers

RuiRong Yuan, MD, PhD – CAHON Board Chair, NJ VA Medical Center

Bo Zhao, MD – CAHON President, Virginia Oncology Associates

Jing-Zhou Hou, MD, PhD – CAHON Board Chair Elect, University of Pittsburgh Medical Center

Liang Deng, MD, PhD – CAHON President Elect, Memorial Sloan Kettering Cancer Center

Delong Liu, MD, PhD – New York Medical College

Speakers



Melissa Johnson – Dr. Melissa Johnson is a medical oncologist whose research focus is new drug development for patients with lung cancer. In 2021, Dr. Johnson assumed the role of director of the Lung Cancer Research Program for Sarah Cannon Research Institute, where she supervises

the lung cancer clinical trial portfolio across the Sarah Cannon network. Johnson is the co-leader of the Immune Effector Cell Therapies program and has directed the development of the Solid Tumor Cellular Therapy program in the Drug Development Unit in Nashville. Prior to joining Sarah Cannon, Johnson was an Associate Professor at Northwestern University and Feinberg School of Medicine. She earned her medical degree from the University of Pennsylvania. After completing residency in internal medicine at New York Hospital/Weill Cornell Medical Center, she did her fellowship training at Memorial Sloan Kettering Cancer Center where she served one year as chief fellow. She is board certified in internal medicine and medical oncology.



Shen Lin – Professor Shen Lin is primarily engaged in clinical research of anti-tumor new drugs, including early-phase clinical trials and multi-center clinical studies. As the leading Principal Investigator (PI), she led many international and domestic clinical studies,

facilitating the approval of indications for 13 new drugs. She established an integrated clinical and translational research system for gastrointestinal tumors, and also focuses on precision treatment and translational studies of gastrointestinal tumors.

Prof. Shen Lin has led or participated in 15 national and provincial projects, including National Key Research and Development Program, National Natural Science Foundation Major Research Program/Joint Fund/Cultivation Project, 973 Program, and 863 Program. She has published over 200 SCI papers as the first or corresponding author in authoritative journals such as Nature, BMJ, Nature Medicine, Lancet Oncology and JCO. She has been recognized as a world class "Highly Cited Scientist" by Clarivate Analytics. She has authored 48 international and domestic guidelines for the diagnosis and treatment of gastrointestinal tumors, obtained 13 national patents, and holds one software copyright. Her research achievements were adopted by over 30 clinical practice guidelines worldwide and were included in the 2022 Annual Medical Advances in China. Because of her contribution, she won a pioneer award in the 2022 Innovation China's "Leading" Edge Science and Technology." As the first contributor, she received the first prize of Science and Technology Award by Chinese Medical Association, the first prize of Science and Technology Award by China Anti-Cancer Association, and the first prize of the Huaxia Medical Science and Technology Award.



Lillian Siu – Dr. Siu is a senior medical oncologist at Princess Margaret Cancer Centre, and is a Professor of Medicine at the University of Toronto. She is the Director of the Phase I Trials Program, co-leads the Tumor Immunotherapy Program and holds the BMO Chair in Precision

Genomics. Dr. Siu had served on the Board of Directors and is a fellow for the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). Dr. Siu is the 2024-2025 President-Elect of the AACR. Dr. Siu's major research focus is in the area of new anticancer drug development, with respect to phase I trials and head and neck malignancies. Internationally, Dr. Siu was the recipient of the US NCI Michaele C. Christian Award in 2010 and the TAT Honorary Award in 2020. In 2020, Dr. Siu received the International Women Who Conquer Cancer Mentorship Award. Dr. Siu is the 2024 David A. Karnofsky Memorial Award recipient. Dr. Siu has published 400 peer-reviewed manuscripts, and she is the co-Editor-in-Chief for AACR's Cancer Research Communications, and is on the editorial board for Cell and Cancer Cell.

YIA Recipients



Zhaohui Arter, MD – Dr. Zhaouhui Arter graduated from Nanjing Medical University and completed her Internal Medicine residency in Hawaii. She is currently finalizing her Hematology/Oncology fellowship at UCI, where she will continue her career as a Thoracic

Oncologist. Dr. Arter's interests lie in early phase clinical trials, and she is eager to enhance collaboration and communication with members of the CAHON community.



Jennifer Huang, MD, PhD – Dr. Jennifer Huang is a second-year hematology and oncology fellow at the University of Washington and Fred Hutchinson Cancer Center with an interest in leukemia, lymphoma and cellular therapy. She attended Duke University for her medical and

doctorate degrees and then completed her Internal Medicine residency at Washington University in St. Louis. Her training and interactions with patients and mentors led to an interest in hematology and oncology and the desire to further contribute to the field by advancing clinical knowledge and mechanistic understanding of disease. She is currently leading projects on investigating the best treatment strategy for patients with mixed phenotypic acute leukemia and a multi-institutional collaboration investigating real-world outcomes of liso-cel in relapsed/refractory CLL, among others. She aspires to become a clinician-scholar with a focus on leading clinical trials and translational studies of new interventions that can improve efficacy and decrease toxicity for patients with leukemia and lymphoma. Outside of work, she enjoys spending time with her family, hiking, and exploring local good eats.



Vincent Ma, MD – Dr. Vincent Ma is an assistant professor at the University of Wisconsin Carbone Cancer Center who specializes in melanoma and advanced cutaneous malignancies with an emphasis in early phase clinical trials. He is currently the immuno-oncology director of the

phase 1 program at the University of Wisconsin.



Xin (Kevin) Wang, MD, PhD – Dr. Xin Wang's current research focuses on genomically informed clinical trials and biomarker development in CNS and GI cancers. He completed his MD/PhD at the University of Toronto with his PhD focused on brain tumor

genomics. He then attended the Internal Medicine and Medical Oncology residency at the University of Toronto. Dr. Wang is currently conducting fellowship research at the Princess Margaret Cancer Centre with a goal of transitioning to a clinician-investigator position.



Yuhang Zhou, MD, PhD – Dr. Yuhang Zhou is a second-year fellow in Hematology Oncology at the University of Texas at Austin, where he completed his internal medicine residency. He received his medical degree from Tongji Medical College at Huazhong University of Science and

Technology, and his PhD in Genetics from Thomas Jefferson University.



EXPLORE MORE AT HIDDENEGFRTHREATS.COM

*Common mutations include L858R and exon 19 deletions.²¹

EGFR, epidermal growth factor receptor; mNSCLC, metastatic non-small cell lung cancer

References: 1. Chiang AC, Fernandes AW, Pavilack M, et al. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors. BMC Cancer. 2020;20(1):356. 2. Robichaux JP, Elaminy TY, Tan Z. et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018;24(6):638-646. 3. Riess JW, Gandara DR, Frampton GM, et al. Diverse EGFR Exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. J Thorac Oncol. 2018;13(10):1560-1568. 4. Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular characteristics of lung cancers harboring EGFR exon 20 insertion mutations in lung adenocarcinomas: clinical outcomes and response to erlotinib. Cancer. 2015;21(18):3212-3220. 7. Chen D, Song Z, Cheng G, Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations. Onco Targets Ther. 2016;9;4181-4186. 8. Bazhenova L, Minchom A, Viter S, et al. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer. 2021;164:19. 9. Bauml J. Viter IS, Minchom A et al. Underdiagnosis of EGFR exon 20 insertion mutation variants: estimates from NGS-based real-world datasets. Presented at the IASLC 2020 World Conference on Lung Cancer, January 28-31. 2021. Singapore. 10. Burnett H, Emich H, Carroll C, Stapleton N, Mahadevia P, Li T. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small-cell lung cancer a systematic literature review. PLoS One. 2021;16(3):e0247620. 11. Lin J, Li M, Chen S, Weng L, He Z. Efficacy and safety of first-generation EGFR-TKIs combined with chemotherapy for treatment-naïve advanced non-small-cell lung cancer patients harboring sensitive EGFR mutations: a single-cen



	_	
-		-
		36
 		_





Chinese American Hematologist and Oncologist Network (CAHON)